Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

Recruiting now · Phase 2

Conditions studied: ANCA Associated Vasculitis (AAV)

In brief

The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)

Key facts

Study ID

NCT06868290

Run by

Novartis Pharmaceuticals

People needed

126

Starts

2025-03-13

Expected to finish

2030-05-24

Last updated by the study team

2026-05-20

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University Of Colorado — Aurora, Colorado, United States (enrolling)
• Mayo Clinic Jacksonville — Jacksonville, Florida, United States (enrolling)
• Northwestern University — Chicago, Illinois, United States (enrolling)
• Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
• Michigan Med University of Michigan — Ann Arbor, Michigan, United States (enrolling)
• University of Minnesota — Minneapolis, Minnesota, United States (enrolling)
• Mayo Clinic Rochester — Rochester, Minnesota, United States (enrolling)
• Oregon Health Sciences University — Portland, Oregon, United States (enrolling)
• Baylor University Medical Center — Dallas, Texas, United States (enrolling)
• Houston Methodist Hospital — Houston, Texas, United States (enrolling)
• LDS Hospital — Salt Lake City, Utah, United States (enrolling)
• Novartis Investigative Site — Salvador, Estado de Bahia, Brazil (enrolling)
• Novartis Investigative Site — Barretos, São Paulo, Brazil (enrolling)
• Novartis Investigative Site — São Paulo, São Paulo, Brazil (enrolling)
• Novartis Investigative Site — São Paulo, Brazil (enrolling)
• Novartis Investigative Site — Haifa, Israel (enrolling)
• Novartis Investigative Site — Ramat Gan, Israel (enrolling)
• Novartis Investigative Site — Sapporo, Hokkaido, Japan (enrolling)
• Novartis Investigative Site — Kobe, Hyōgo, Japan (enrolling)
• Novartis Investigative Site — Sendai, Miyagi, Japan (enrolling)
• Novartis Investigative Site — Suita, Osaka, Japan (enrolling)
• Novartis Investigative Site — Bunkyo Ku, Tokyo, Japan (enrolling)
• Novartis Investigative Site — Shinjuku-ku, Tokyo, Japan (enrolling)
• Novartis Investigative Site — Chiba, Japan (enrolling)
• Novartis Investigative Site — Fukuoka, Japan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.